Press release
From mechanism of action to prospective immunotherapeutic methods, TIGIT in cancer
TIGIT Inhibitors Market
The field of immuno-oncology has revolutionized cancer treatment, with checkpoint inhibitors such as PD-1, PD-L1, and CTLA-4 therapies transforming outcomes for patients with advanced malignancies. However, many patients still fail to respond or develop resistance, underscoring the need for new immune checkpoint targets. T-cell immunoreceptor with Ig and ITIM domains (TIGIT) has emerged as one of the most promising next-generation targets, showing strong potential to enhance anti-tumor immunity when combined with PD-1/PD-L1 inhibitors.
Over the next decade, the TIGIT inhibitors market is expected to expand significantly, driven by increasing clinical trial activity, rising cancer incidence, and growing collaborations between global pharmaceutical leaders and biotech innovators.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/72666
Market Overview
• The global TIGIT inhibitors market size in 2024 is estimated at USD 210 million.
• It is projected to reach USD 3.2 billion by 2034, growing at a striking CAGR of 31.1 % during the forecast period.
• Growth is supported by robust pipelines, particularly in non-small cell lung cancer (NSCLC), melanoma, and other solid tumors.
Key Market Drivers:
• Rising prevalence of cancer worldwide.
• Expanding immuno-oncology pipeline with multiple TIGIT inhibitor candidates.
• Strong synergy of TIGIT inhibitors with PD-1/PD-L1 checkpoint blockade.
• Increasing investment in clinical trials and global collaborations.
Key Challenges:
• Limited late-stage clinical trial successes to date.
• Safety and tolerability concerns in combination regimens.
• High R&D and clinical trial costs.
Leading Players:
Roche/Genentech, Merck & Co., Bristol Myers Squibb, Gilead Sciences, BeiGene, Innovent Biologics, Arcus Biosciences, Compugen, and Iteos Therapeutics.
Segmentation Analysis
The TIGIT inhibitors market can be segmented as follows:
By Drug Type
• Monoclonal Antibodies
• Bispecific Antibodies (TIGIT + PD-1/PD-L1)
• Others (fusion proteins, experimental formats)
By Cancer Indication
• Non-Small Cell Lung Cancer (NSCLC)
• Melanoma
• Head & Neck Squamous Cell Carcinoma
• Colorectal Cancer
• Others (hematologic malignancies, urothelial carcinoma)
By End-Use
• Hospitals
• Cancer Treatment Centers
• Research & Academic Institutes
Summary:
Monoclonal antibodies dominate current pipelines, but bispecific antibodies targeting TIGIT and PD-1/PD-L1 simultaneously are gaining strong interest due to their potential for improved efficacy. NSCLC remains the largest therapeutic focus, though melanoma and other cancers represent key growth areas.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/72666/tigit-inhibitors-market
Regional Analysis
North America
• Largest market, accounting for ~50 % of global revenues in 2024.
• Strong clinical trial presence, especially in the U.S.
• Robust investment in immuno-oncology R&D by major players such as Merck, BMS, and Genentech.
Europe
• Significant adoption in Germany, France, and the UK, supported by EMA's rare disease and oncology frameworks.
• Expanding partnerships between European biotech startups and pharma leaders.
Asia-Pacific (APAC)
• Expected to record the fastest CAGR (~34.2 %) during 2024-2034.
• China is a major hub, with BeiGene and Innovent Biologics leading TIGIT-focused pipelines.
• Expanding oncology trials in Japan, South Korea, and India.
Middle East & Africa (MEA)
• Early adoption stage, with oncology growth driven by rare disease and immunotherapy programs in Gulf nations.
Latin America
• Brazil and Mexico lead in clinical adoption, with growing involvement in international immuno-oncology studies.
Regional Summary:
North America and Europe dominate current revenues, but Asia-Pacific will be the fastest-growing hub, fueled by biotech innovation and rapidly expanding cancer patient populations.
Market Dynamics
Growth Drivers
1. Increasing cancer incidence globally (19+ million new cases annually).
2. Strong therapeutic synergy of TIGIT inhibitors with PD-1/PD-L1 drugs.
3. Expanding pipeline with dozens of clinical trials underway.
4. Rising investments in immuno-oncology from both pharma and biotech firms.
Key Challenges
• Clinical trial attrition and regulatory hurdles.
• Safety profile concerns in immune-related adverse events.
• Pricing and reimbursement issues in oncology markets.
Latest Trends
• Development of bispecific and multispecific antibodies targeting TIGIT in combination with PD-1, LAG-3, and other checkpoints.
• Increasing use of biomarker-driven patient selection to improve trial success.
• Growth in strategic licensing and partnership agreements between biotech startups and large pharma.
• Exploration of TIGIT inhibition in autoimmune diseases beyond oncology.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72666
Competitor Analysis
Major Players:
• Roche/Genentech (tiragolumab - leading TIGIT inhibitor candidate).
• Merck & Co. (pipeline combination studies with Keytruda).
• Bristol Myers Squibb (early-stage TIGIT programs).
• Gilead Sciences & Arcus Biosciences (domvanalimab, in advanced trials).
• BeiGene (ociperlimab - extensive development in China).
• Innovent Biologics (pipeline TIGIT inhibitors for NSCLC).
• Compugen (preclinical and clinical checkpoint programs).
• Iteos Therapeutics (EOS-448 - bispecific development).
Competitive Summary:
The market is highly innovation-driven, with Roche's tiragolumab and Arcus/Gilead's domvanalimab leading the race. Asian players like BeiGene and Innovent are shaping APAC's rapid growth, while U.S. biotech firms such as Arcus, Compugen, and Iteos are advancing differentiated approaches. Partnerships and co-development deals are critical for trial funding and accelerating commercialization.
Conclusion
The TIGIT inhibitors market is projected to grow from USD 210 million in 2024 to USD 3.2 billion by 2034, at a CAGR of 31.1 %.
This report is also available in the following languages : Japanese (TIGIT阻害剤市場), Korean (TIGIT 억제제 시장), Chinese (TIGIT抑制剂市场), French (Marché des inhibiteurs TIGIT), German (Markt für TIGIT-Inhibitoren), and Italian (Mercato degli inibitori TIGIT), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/72666
Our More Reports:
Dermal Fillers Market
https://exactitudeconsultancy.com/reports/72408/dermal-fillers-market
GLP-1 Market
https://exactitudeconsultancy.com/reports/72406/glp-1-market
Sterile Injectable Contract Manufacturing Market
https://exactitudeconsultancy.com/reports/72404/sterile-injectable-contract-manufacturing-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release From mechanism of action to prospective immunotherapeutic methods, TIGIT in cancer here
News-ID: 4202297 • Views: …
More Releases from Exactitude Consultancy
Epstein-Barr Is Riskier Than You May Imagine
Introduction
The Epstein-Barr virus (EBV), a member of the herpesvirus family, is one of the most common human viruses, infecting nearly 90-95 % of the global population at some point in their lives. EBV is the primary cause of infectious mononucleosis ("mono") and is linked to several serious conditions, including Hodgkin's lymphoma, Burkitt's lymphoma, nasopharyngeal carcinoma, and multiple sclerosis (MS).
Despite its widespread prevalence and serious long-term health associations, no approved vaccines…
Plexiform Neurofibroma Market to Reach USD 1.1 Billion by 2034, Growing at 10.7% …
Introduction
Plexiform neurofibroma (PN) is a rare, benign but potentially disfiguring and debilitating tumor associated with neurofibromatosis type 1 (NF1), a genetic disorder caused by mutations in the NF1 gene. While benign, these tumors can grow extensively along nerves, leading to pain, functional impairment, and, in some cases, malignant transformation into malignant peripheral nerve sheath tumors (MPNSTs).
Historically, treatment options were limited to surgery, often complicated by high recurrence rates and incomplete…
Angiomatosis Market to Reach USD 740 Million by 2034, Growing at 9.2% CAGR
Introduction
Angiomatosis is a rare, benign condition characterized by the proliferation of blood vessels, often presenting as diffuse vascular lesions that can affect skin, soft tissues, or internal organs. Although non-malignant, angiomatosis can cause significant health complications, including bleeding, disfigurement, pain, and functional impairment, depending on the site of occurrence.
Due to its rarity, angiomatosis has historically been underdiagnosed and undertreated. Current therapeutic approaches include surgical excision, embolization, laser therapy, and systemic…
C3 Glomerulopathy Market Emerging Therapeutics for a Rare Kidney Disorder
Introduction
C3 glomerulopathy (C3G) is a rare, progressive kidney disease characterized by abnormal complement system activation, leading to deposition of complement protein C3 in the glomeruli. This results in chronic kidney damage, proteinuria, hematuria, and progressive loss of renal function, often culminating in end-stage renal disease (ESRD).
Due to its rarity and complex pathology, C3G has historically lacked effective treatment options, with patients often managed using non-specific therapies like immunosuppressants or dialysis.…
More Releases for TIGIT
Development and Optimization of Next-Generation TIGIT Antibodies
The development and optimization of next-generation TIGIT antibodies represent a significant advancement in cancer immunotherapy. These antibodies are designed to target the TIGIT immune checkpoint more effectively, offering improved therapeutic potential for enhancing anti-tumor immune responses.
Download Report
https://www.kuickresearch.com/report-anti-tigit-antibody-anti-tigit-antibodies-fda-approved-tigit-antibody-tigit-inhibitors-tigit-drugs-approved-tigit-expression-tigit-ligand-tigit-gene
The initial development of TIGIT antibodies focused on blocking the interaction between TIGIT and its ligands, CD155 and CD112. By preventing this binding, the inhibitory signals transmitted by TIGIT are lifted, allowing immune cells…
The Future of TIGIT Antibodies in Personalized Cancer Treatment
The future of TIGIT antibodies in personalized cancer treatment looks promising, with the potential to revolutionize the way we approach cancer therapy. Personalized medicine aims to tailor treatments based on individual patient characteristics, including genetic, molecular, and immune profiles. TIGIT antibodies, by targeting a specific immune checkpoint, offer a new avenue for customizing cancer treatment and improving patient outcomes.
Download Report
https://www.kuickresearch.com/report-anti-tigit-antibody-anti-tigit-antibodies-fda-approved-tigit-antibody-tigit-inhibitors-tigit-drugs-approved-tigit-expression-tigit-ligand-tigit-gene
TIGIT, an inhibitory receptor expressed on T cells, NK cells, and…
Comparative Effectiveness of TIGIT Antibodies and Other Checkpoint Inhibitors
The comparative effectiveness of TIGIT antibodies and other checkpoint inhibitors is a topic of significant interest in the field of cancer immunotherapy. Immune checkpoint inhibitors have revolutionized cancer treatment by unleashing the immune system's ability to attack tumors. While PD-1 and CTLA-4 inhibitors have shown remarkable success, TIGIT antibodies offer a new approach with potentially complementary mechanisms.
Download Report
https://www.kuickresearch.com/report-anti-tigit-antibody-anti-tigit-antibodies-fda-approved-tigit-antibody-tigit-inhibitors-tigit-drugs-approved-tigit-expression-tigit-ligand-tigit-gene
PD-1 inhibitors, such as pembrolizumab and nivolumab, block the PD-1 receptor on T…
Biomarkers for Predicting Response to TIGIT Antibody Therapy
Identifying biomarkers for predicting response to TIGIT antibody therapy is crucial for optimizing treatment outcomes and personalizing cancer therapy. Biomarkers can help select patients who are most likely to benefit from TIGIT blockade, thereby improving the efficacy and reducing unnecessary exposure to the therapy.
Download Report
https://www.kuickresearch.com/report-anti-tigit-antibody-anti-tigit-antibodies-fda-approved-tigit-antibody-tigit-inhibitors-tigit-drugs-approved-tigit-expression-tigit-ligand-tigit-gene
One of the most promising biomarkers for TIGIT antibody therapy is the expression level of CD155, the primary ligand for TIGIT. High levels of CD155 expression…
Innovations in Immunotherapy The Rise of Anti TIGIT Antibodies
Innovations in immunotherapy have transformed the landscape of cancer treatment, offering new hope to patients who previously had limited options. Among these innovations, the rise of anti-TIGIT antibodies represents a significant advancement in the field, providing a novel approach to enhancing the immune system's ability to combat cancer. Anti-TIGIT antibodies are a new class of immune checkpoint inhibitors that target TIGIT, an inhibitory receptor expressed on T-cells, natural killer (NK)…
Anti TIGIT Antibodies Revolutionizing Immunotherapy
Anti-TIGIT antibodies are at the forefront of a revolution in immunotherapy, representing a new class of immune checkpoint inhibitors that have the potential to transform the treatment landscape for cancer. Immunotherapy, which harnesses the body's immune system to fight cancer, has already made significant strides with the introduction of PD-1, PD-L1, and CTLA-4 inhibitors. However, the discovery and development of anti-TIGIT antibodies add a new dimension to this field, offering…
